Celldex Therapeutics, Inc.  

(Public, NASDAQ:CLDX)   Watch this stock  
Find more results for CLDX
+0.51 (7.57%)
After Hours: 7.24 -0.01 (-0.14%)
Feb 12, 6:49PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.57 - 7.33
52 week 6.25 - 32.82
Open 6.82
Vol / Avg. 2.92M/3.23M
Mkt cap 747.34M
P/E     -
Div/yield     -
EPS -1.33
Shares 98.65M
Beta 3.66
Inst. own 92%
Feb 22, 2016
Q4 2015 Celldex Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 11, 2016
Celldex Therapeutics Inc at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -3116.96% -3292.80%
Operating margin -3155.07% -3414.11%
EBITD margin - -3319.27%
Return on average assets -34.86% -39.68%
Return on average equity -38.61% -44.44%
Employees 161 -
CDP Score - -


519 Route 173 West
United States - Map
+1-302-6587581 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Officers and directors

Larry Ellberger Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Anthony S Marucci President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Avery W. Catlin CPA Chief Financial Officer, Senior Vice President, Secretary
Age: 66
Bio & Compensation  - Reuters
Tibor Keler Ph.D. Executive Vice President and Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Thomas Andrew Davis M.D. Executive Vice President and Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Ronald A. Pepin Ph.D. Senior Vice President and Chief Business Officer
Age: 59
Bio & Compensation  - Reuters
Richard Wright Ph.D. Senior Vice President, Chief Commercial Officer`
Bio & Compensation  - Reuters
Herbert J. Conrad Independent Director
Age: 82
Bio & Compensation  - Reuters
George O. Elston CPA Independent Director
Age: 50
Bio & Compensation  - Reuters
Harry H. Penner Jr., J.D. Independent Director
Age: 69
Bio & Compensation  - Reuters